Development, validation, and application of a quantitative volumetric absorptive microsampling–based method in finger prick blood by means of LC-HRMS/MS applicable for adherence monitoring of antipsychotics

被引:0
作者
Cathy M. Jacobs
Lea Wagmann
Markus R. Meyer
机构
[1] Saarland University,Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS)
来源
Analytical and Bioanalytical Chemistry | 2021年 / 413卷
关键词
Adherence monitoring; Microsampling; VAMS; Antipsychotics; LC-HRMS;
D O I
暂无
中图分类号
学科分类号
摘要
Volumetric absorptive microsampling (VAMS), an emerging microsampling technique, is expected to overcome some disadvantages of dried blood spots such as volume inaccuracy and influence of hematocrit (HT). This study aimed to develop and evaluate a VAMS-based strategy for quantification of 13 frequently prescribed antipsychotics in finger prick blood within the scope of adherence monitoring to complement already-established qualitative urine analysis. The final workflow consisted of VAMS tip hydration and subsequent precipitation. Samples were analyzed by using reversed-phase ultra-high-performance liquid chromatography and Orbitrap mass spectrometry operated in parallel reaction monitoring mode. The analytical procedure was successfully validated based on international recommendations at three different HT values (20%, 40%, 60%) for most of the analytes. Selectivity and within/between-run accuracy and precision were in accordance with the recommendations in most cases. Internal standard–normalized matrix factor met recommended criteria for all analytes at HT 40%. For the HT values of 20% and 60%, only four substances did not meet the criteria. Dilution integrity was given for all substances, except for olanzapine, allowing a quantification over the whole therapeutic range of selected antipsychotics. Long-term stability in VAMS tips was tested and revealed degradation of five antipsychotic drugs after 1 week of storage at 24 °C. A proof of concept of the applicability of the method was obtained by quantification of a selection of the 13 antipsychotic drugs in VAMS tips and matched plasma samples. Results were coherent between matrices. Thus, VAMS was shown to be a promising alternative for adherence monitoring of at least the investigated antipsychotics.
引用
收藏
页码:1729 / 1737
页数:8
相关论文
共 168 条
[1]  
Pfennig A(2013)The diagnosis and treatment of bipolar disorder: recommendations from the current s3 guideline Dtsch Arztebl Int 110 92-100
[2]  
Bschor T(2019)A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia Int Rev Psychiatry 31 441-459
[3]  
Falkai P(2016)Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review J Clin Psychopharmacol 36 355-371
[4]  
Bauer M(2014)Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies Patient Relat Outcome Meas 5 43-62
[5]  
Hui CLM(2018)Medication nonadherence in bipolar disorder: a narrative review Ther Adv Psychopharmacol. 8 349-363
[6]  
Lam BST(2012)Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims Int J Clin Pract 66 565-573
[7]  
Lee EHM(2020)Adherence to neuroleptic treatment in psychiatric practices: a retrospective study of 55 practices with more than 5000 bipolar and schizophrenic patients in Germany Psychiatry Res 284 112758-218
[8]  
Chan SKW(2013)Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review Ther Adv Psychopharmacol 3 200-647
[9]  
Chang WC(2007)Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial Arch Gen Psychiatry 64 633-590
[10]  
Suen YN(2010)Treatment options for bipolar depression: a systematic review of randomized, controlled trials J Clin Psychopharmacol 30 579-343